199 related articles for article (PubMed ID: 26558143)
1. Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients.
Pipili C; Cholongitas E
World J Gastrointest Pharmacol Ther; 2015 Nov; 6(4):105-10. PubMed ID: 26558143
[TBL] [Abstract][Full Text] [Related]
2. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.
Cholongitas E; Pipili C; Papatheodoridis G
World J Gastroenterol; 2015 Aug; 21(32):9526-33. PubMed ID: 26327760
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
4. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
Ueda Y; Ikegami T; Akamatsu N; Soyama A; Shinoda M; Goto R; Okajima H; Yoshizumi T; Taketomi A; Kitagawa Y; Eguchi S; Kokudo N; Uemoto S; Maehara Y
J Gastroenterol; 2017 Aug; 52(8):986-991. PubMed ID: 28138756
[TBL] [Abstract][Full Text] [Related]
5. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis.
Liu J; Ma B; Cao W; Li M; Bramer WM; Peppelenbosch MP; Pan Q
Transpl Infect Dis; 2019 Apr; 21(2):e13047. PubMed ID: 30615227
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?
Pipili C; Cholongitas E
World J Hepatol; 2015 Jun; 7(12):1606-16. PubMed ID: 26140081
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
[TBL] [Abstract][Full Text] [Related]
10. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
[TBL] [Abstract][Full Text] [Related]
11. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
13. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
[TBL] [Abstract][Full Text] [Related]
14. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
Raschzok N; Schott E; Reutzel-Selke A; Damrah I; Gül-Klein S; Strücker B; Sauer IM; Pratschke J; Eurich D; Stockmann M
Transpl Infect Dis; 2016 Dec; 18(6):896-903. PubMed ID: 27632190
[TBL] [Abstract][Full Text] [Related]
15. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Crittenden NE; Buchanan LA; Pinkston CM; Cave B; Barve A; Marsano L; McClain CJ; Jones CM; Marvin MR; Davis EG; Kuns-Adkins CB; Gedaly R; Brock G; Shah MB; Rosenau J; Cave MC
Liver Transpl; 2016 May; 22(5):635-43. PubMed ID: 26915588
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Saxena V; Khungar V; Verna EC; Levitsky J; Brown RS; Hassan MA; Sulkowski MS; O'Leary JG; Koraishy F; Galati JS; Kuo AA; Vainorius M; Akushevich L; Nelson DR; Fried MW; Terrault N; Reddy KR
Hepatology; 2017 Oct; 66(4):1090-1101. PubMed ID: 28504842
[TBL] [Abstract][Full Text] [Related]
17. Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant.
Shoreibah M; Orr J; Jones D; Zhang J; Venkata K; Massoud O
Hepatol Int; 2017 Sep; 11(5):434-439. PubMed ID: 28083718
[TBL] [Abstract][Full Text] [Related]
18. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
Fabrizi F; Martin P; Messa P
Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
Kamar N; Marion O; Rostaing L; Cointault O; Ribes D; Lavayssière L; Esposito L; Del Bello A; Métivier S; Barange K; Izopet J; Alric L
Am J Transplant; 2016 May; 16(5):1474-9. PubMed ID: 26587971
[TBL] [Abstract][Full Text] [Related]
20. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
